Irina Pruchansky, DO
Family Medicine · Brooklyn, NYNPI 1811080351
Payments from drug & device makers
Across 346 payments — averaging $20.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Novo Nordisk$711
- Bayer$689
- Arbor Pharmaceuticals, Inc.$273
- Johnson & Johnson$258
- plus $2K from 31 others
What the payments were for
- Food & beverage$7,015100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 77 | $1,563 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 53 | $1,039 |
| Novo Nordisk | 41 | $711 |
| Bayer | 28 | $689 |
| Arbor Pharmaceuticals, Inc. | 13 | $273 |
| Johnson & Johnson | 12 | $258 |
| Amgen(2 entities) | 11 | $246 |
| Lilly USA, LLC | 11 | $226 |
| Merck | 15 | $209 |
| Ironwood Pharmaceuticals, Inc | 8 | $166 |
| Azurity Pharmaceuticals, Inc. | 7 | $151 |
| Amarin Pharma, Inc. | 8 | $150 |
| Sanofi-aventis U.S. LLC | 8 | $132 |
| Medtronic | 1 | $127 |
| Amneal Pharmaceuticals LLC | 6 | $122 |
| AstraZeneca | 6 | $122 |
| Pfizer | 5 | $102 |
| Nestle Healthcare Nutrition Inc. | 4 | $84 |
| Aimmune Therapeutics, Inc. | 3 | $78 |
| Novartis | 3 | $67 |
| E.r. Squibb & Sons, L.L.C. | 4 | $63 |
| Ardelyx, Inc. | 2 | $53 |
| Vivus LLC | 3 | $51 |
| Biohaven Pharmaceuticals, Inc. | 3 | $51 |
| GSK | 2 | $47 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27 |
| Bausch Health US, LLC | 1 | $24 |
| Gilead | 1 | $23 |
| Kowa Pharmaceuticals America, Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $20 |
| Bristol Myers Squibb | 1 | $20 |
| Shield Therapeutics Inc | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Scilex Pharmaceuticals Inc. | 1 | $19 |
| Heartflow, Inc. | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Creon$302
- ILLUMISITE$127
- XIFAXAN$125
How this compares
$7,022 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 318 | $347,193 |
| EliquisApixaban | 465 | $293,253 |
| OzempicSemaglutide | 281 | $278,257 |
| ZenpepLipase/Protease/Amylase | 138 | $178,370 |
| LinzessLinaclotide | 335 | $178,362 |
| JanumetSitagliptin Phos/Metformin Hcl | 220 | $131,165 |
| Diclofenac Sodium | 267 | $117,679 |
| RybelsusSemaglutide | 110 | $109,636 |
| JanuviaSitagliptin Phosphate | 188 | $105,054 |
| VascepaIcosapent Ethyl | 242 | $82,637 |
| TradjentaLinagliptin | 160 | $81,741 |
| JardianceEmpagliflozin | 119 | $78,141 |
| ProliaDenosumab | 48 | $77,635 |
| XareltoRivaroxaban | 102 | $72,431 |
| EdarbiAzilsartan Medoxomil | 292 | $70,977 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess, Synthroid | $1,563 | $554,8591,306 claims |
| Novo NordiskOzempic, Rybelsus | $711 | $387,893391 claims |
| PfizerEliquis | $102 | $293,253465 claims |
| MerckJanumet, Januvia, Belsomra | $209 | $254,658451 claims |
| Boehringer IngelheimTradjenta, Jardiance, Jentadueto | $15 | $179,338320 claims |
| Aimmune Therapeutics, Inc.Zenpep | $78 | $178,370138 claims |
| Arbor Pharmaceuticals, Inc.Edarbi, Horizant, Edarbyclor | $273 | $115,016404 claims |
| AmgenProlia | $246 | $77,63548 claims |
| NovartisSandostatin Lar Depot, Entresto | $67 | $76,24940 claims |
| Johnson & JohnsonXarelto | $258 | $72,431102 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $1,039 | $47,76790 claims |
| Lilly USA, LLCTrulicity | $226 | $39,68542 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.
Other family medicine in Brooklyn
- Michael YuryevBrooklyn$589K
- Matthew SpitzerBrooklyn$469K
- Walford LindoBrooklyn$104K
- Fu Fu HeBrooklyn$101K
- Jonathan ChangBrooklyn$66K
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.